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Most patients with glucose transporter type 1 (GLUT1) deﬁciency syndrome (G1D) experience
anticonvulsant-refractory epilepsy and abnormal cognitive and motor development.1 Ninety
percent of patients with G1D harbor a causative loss-of-function mutation in the SLC2A1 gene; in
the others, brain ﬂuorodeoxyglucose (FDG) PET can conﬁrm the diagnosis.
G1D investigation has centered on the cerebral aspects of the disease, but extracerebral manifestations are plausible.1 The eye is a likely substrate: retinal GLUT1 sustains ocular glucose
transport based on its expression in Müller, vascular endothelial, and pigmentary epithelial cells.
Notably, GLUT1 is a target for diabetic retinopathy drugs.2,3 We describe retinal abnormalities in
a patient with G1D in the broader context of the plausible mechanisms and consequences of
retinal GLUT1 loss of function or therapeutic inhibition.

Case report
A 20-year-old woman with the common epileptic form of G1D reported subnormal visual acuity
uncorrectable with glasses and harbored a de novo pathogenic SLC2A1 variant (c.1454C>T;
P485L).1,4 The mutation introduced a dileucine motif in GLUT1 associated with clathrin recruitment and excessive internalization of cell membrane GLUT1.5
Her visual acuity was 20/40 (OD) and 20/30 (OS) with no other obvious ocular abnormalities.
Optical coherence tomography (OCT) revealed retinal thinning in the posterior pole respecting
the fovea (ﬁgure 1, A and B) and absence of the interdigitation band peripherally with moderate
photoreceptor layer thinning (ﬁgure 1, C and D). Swept source OCT demonstrated signiﬁcant
choroidal thickening (571 and 495 μm in the OD and OS, respectively; normal for age:
;330–400 μm). Retinal fundus autoﬂuorescence (FAF) demonstrated hyperautoﬂuorescence
outside the fovea and an unusual hyperautoﬂuorescence in the central fovea (ﬁgure 1, E and F).
OCT-angiography (OCTA) showed a paucity of perimacular vessels (ﬁgure 1, G and H).
There were functional correlates to these ﬁndings, including multiple D-15 Farnsworth color
testing defects in the protan axis bilaterally and suppressed cone ﬂicker amplitudes with normal
rod system electroretinography (ERG) responses (ﬁgure e-1, links.lww.com/NXG/A276). Repeat testing over 1 year was invariant.

Discussion
Our patient with G1D exhibited structural and functional retinal dysfunction. The retinal changes
were congruent across all imaging modalities: the retinal thinning noted on macular color
thickness maps correlated with the hyperautoﬂuorescence on FAF and with the area of reduced
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Figure 1 Retinal multimodal imaging in a patient with GLUT1
deficiency

the retinal pigment epithelium (RPE). This implies that our
patient’s de novo somatic (and therefore uniformly vascular
and glial because there is no reason to suspect mosaicism)
mutation exerts secondary consequences on neurons (which
are largely devoid of GLUT1). This likely stems from reduced glucose (or another mediator) ﬂux across retinal cell
types.
Modest GLUT1 expression changes are functionally relevant:
increased renal GLUT1 has deleterious consequences in diabetic nephropathy.6 Conversely, GLUT1 small interfering
RNAs (siRNAs) reduce retinal glucose and ameliorate diabetic retinopathy, which is accompanied by reduced ERG
signal amplitude and outer nuclear layer thinning.3 This is
analogous to our patient’s diminished cone ﬂicker amplitude
and retinal thickness. Furthermore, diabetic mice exhibit increased RPE GLUT1 expression after prolonged exposure to
hyperglycemia and hypoxia. The resulting elevated RPE glucose can be associated with impaired pigment epitheliumderived (PEDF) secretion, leading to imbalanced vascular
endothelial growth factor (VEGF)/PEDF and stimulated
neovascularization.3 Our patient exhibited reduced capillary
density, which may reﬂect altered VEGF/PEDF release as in
diabetic retinopathy.
Some diabetic retinopathy therapies target GLUT1, including angiotensin-converting enzyme inhibitors such as
captopril. This occurs, in part, via decreased retinal glucose
after the reduction of GLUT1-mediated glucose transport
(despite unaltered GLUT1 expression). Intraocular siRNA
diminishes GLUT1 expression in the inner blood-retinal
barrier of streptozotocin-diabetic mice and decreases retinal
glucose.3 Last, GLUT1 inhibition by forskolin or genistein in
diabetic mice leads to similar results. In all these contexts,
retinal glucose decreases after treatment, suggesting that
GLUT1 inhibition can counteract the end result of multifactorial diabetic retinopathy.

(A and B) Optical coherence tomography (OCT) total macular color thicknessmaps (in microns) showing marked retinal thinning (blue-purple area)
outside the fovea in the right and left eyes, respectively. (C and D) OCT b-scans
at the foveal centers demonstrate thickened retinal pigment epithelial layer
interdigitation bands (red arrows) only at the foveal centers; the bands disappear in the periphery of the scans. (E and F) Wide-field fundus autofluorescence (FAF) images of the right and left eye, respectively, showing
increased FAF in the perifoveal area corresponding to the area of retinal
thinning depicted in (A and B). Note that the fovea demonstrates subtle but
abnormal hyperautofluorescence centrally; this area normally shows hypoautofluorescence because of macular pigment AF blockage. (G and H) OCT
angiography (OCTA) of the superficial capillary plexus demonstrates decreased perimacular vessel density. (A–F) See figure e-2 (links.lww.com/NXG/
A276) for comparison of all images to those of a normal subject.

However, GLUT1 inhibition may be detrimental to photoreceptor and RPE cells. In mice, reduction of RPE glucose
via GLUT1 knockout results in outer segment shortening,
photoreceptor cell death, and Müller cell activation. This
underscores the importance of near-constant GLUT1 activity in the retina.7 Our ﬁndings suggest that these experimental observations are likely relevant in humans,
suggesting that therapeutic GLUT1 inhibition may result in
undesired eﬀects.

Conclusions
vessel density on OCTA. Together with the thickened choroid
and decreased cone ﬂicker, the simplest interpretation of our
ﬁndings is early onset photoreceptor degeneration.
In the retina, Glut1-mediated transport occurs across capillary endothelial cells of the inner blood-retinal barrier and
2
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Our case demonstrates the contribution of nonneural GLUT1
to retinal cell (including photoreceptor) activity and vision.
Although diabetic retinopathy therapies that inhibit GLUT1
are plausible, this inhibition may be detrimental. This case
also illustrates the value of retinal assessment in G1D and in
those receiving GLUT1-related diabetes therapies.
Neurology.org/NG
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